CCST conducts many research projects at its Christchurch location. Currently a trial is underway to see if Perjeta (a drug often given with Herceptin to women who have breast cancer) can be given SC- sub cutaneously. Currently Perjeta has to be given IV as a slow injection into a vein. The trial aims to find the SC dose that most closely matches the IV dose and see how safe and well tolerated SC Perjeta is.
Findings from this trial could really help women undergoing treatment for breast cancer as often women undergoing treatment have complications from long term IV cancer treatments.